Inflammatory monocytes recruited after skeletal muscle injury switch into antiinflammatory macrophages to support myogenesis by Arnold, Ludovic et al.
T
h
e
 
J
o
u
r
n
a
l
 
o
f
 
E
x
p
e
r
i
m
e
n
t
a
l
 
M
e
d
i
c
i
n
e
ARTICLE
JEM © The Rockefeller University Press  $15.00
Vol. 204, No. 5,  May 14, 2007  1057–1069  www.jem.org/cgi/doi/10.1084/jem.20070075
1057
Stromal cells are involved in organogenic pro-
cesses by controlling parenchymal cell functions 
such as migration, proliferation, diff  erentiation, 
and programmed cell death (1). Among stromal 
cells, macrophages (MPs) play a major role in 
the maintenance of tissue homeostasis (2). In ad-
dition to phagocytosis and antigen presentation, 
these cells play a supportive function in various 
tissues (2, 3). However, MPs are renowned for 
their heterogeneity, as refl  ected by the various 
specialized functions they adopt in diff  erent ana-
tomical locations (2, 4). Many of these activities 
appear to be opposing in nature (e.g., proinfl  am-
matory vs. antiinfl  ammatory, immunogenic vs. 
tolerogenic, and tissue-destructive vs. tissue-
repair activities) (4).
Diff  erent activation states have been de-
scribed in vitro for MPs, each being associated 
with a particular phenotype and function (2, 5). 
Classical activation, obtained after LPS/IFN-γ 
treatment, induces production of proinfl  am-
matory cytokines and reactive oxygen species. 
Alternative activation, obtained after IL-4 treat-
ment, increases expression of the mannose 
receptor (CD206). Deactivation by IL-10 and 
glucocorticoids induces production of IL-10, 
TGF-β1, and expression of the scavenger re-
ceptor CD163. However, it is not known to 
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Macrophages (MPs) are important for skeletal muscle regeneration in vivo and may exert 
benefi  cial effects on myogenic cell growth through mitogenic and antiapoptotic activities 
in vitro. However, MPs are highly versatile and may exert various, and even opposite, func-
tions depending on their activation state. We studied monocyte (MO)/MP phenotypes and 
functions during skeletal muscle repair. Selective labeling of circulating MOs by latex beads 
in CX3CR1GFP/+ mice showed that injured muscle recruited only CX3CR1lo/Ly-6C+ MOs from 
blood that exhibited a nondividing, F4/80lo, proinfl  ammatory profi  le. Then, within muscle, 
these cells switched their phenotype to become proliferating antiinfl  ammatory CX3CR1hi/
Ly-6C− cells that further differentiated into F4/80hi MPs. In vitro, phagocytosis of muscle 
cell debris induced a switch of proinfl  ammatory MPs toward an antiinfl  ammatory pheno-
type releasing transforming growth factor 𝗃1. In co-cultures, infl  ammatory MPs stimulated 
myogenic cell proliferation, whereas antiinfl  ammatory MPs exhibited differentiating activity, 
assessed by both myogenin expression and fusion into myotubes. Finally, depletion of 
circulating MOs in CD11b–diphtheria toxin receptor mice at the time of injury totally 
prevented muscle regeneration, whereas depletion of intramuscular F4/80hi MPs at later 
stages reduced the diameter of regenerating fi  bers. In conclusion, injured skeletal muscle 
recruits MOs exhibiting infl  ammatory profi  les that operate phagocytosis and rapidly 
convert to antiinfl  ammatory MPs that stimulate myogenesis and fi  ber growth.
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what extent these distinct activation states exist in vivo 
and whether MP fate is determined forever or whether it 
remains constantly malleable (2), although several in vitro 
studies have shown MP adaptation to a changing microenvi-
ronment (4, 6–8).
An additional degree of complexity is reached with the 
existence of several subsets of circulating monocytes (MOs). 
In both the human and mouse, two main MO subsets are 
present in blood: the main CD14hi CD16− (CX3CR1lo/Ly-
6Chi in the mouse) MO subset that invades tissues during 
acute infl  ammation and the CD14lo CD16+ (CX3CR1hi/Ly-
6Clo in the mouse) MO subset, which is not (or to a lesser 
extent) recruited during infl  ammation (9–13) but is expanded 
in chronic diseases such as HIV infection, sepsis, tuberculosis, 
or asthma (14). Both fate and function of this population re-
main unclear, because in mouse, it is present in the normal 
spleen and may correspond to MPs residing in normal tissues (9). 
However, there is growing evidence that they may result 
from the maturation of Ly-6Chi MOs (11, 15, 16).
MPs are involved in skeletal muscle repair. Muscle dam-
age induces massive MP infi  ltration at the injury site (17, 18). 
Partial depletion of MOs/MPs impairs muscle regeneration, 
whereas reconstitution of bone marrow restores regeneration 
(19–23). Initially limited to phagocytosis of necrotic fi  bers, 
the proregenerative role of MPs has been shown to involve a 
direct stromal support function (24, 25). We have previously 
shown that MO-derived MPs enhance myogenic cell growth 
(26). MPs release mitogenic growth factors for myogenic 
precursor cells (mpcs) and establish cell–cell interactions 
that protect mpcs from apoptosis (26, 27). However, little is 
known about both MO/MP subsets and phenotypes at work 
during muscle regeneration. Studies in the rat have shown 
that ED1+ MPs are associated with muscle necrosis, whereas 
ED2+ (CD163) MPs, regarded as “resident MPs,” invade muscle 
Figure 1.  Kinetics of MO/MP subsets during muscle regeneration 
in the CX3CR1GFP/+ mouse. (A) CD45+ cells present in injured muscle 
were analyzed for Ly-6C and GFP (CX3CR1) expression by fl  ow cytometry. 
(top) Results are expressed as the percentage of CD45+ cells isolated from 
muscle and represent the means ± SD of three experiments. (bottom) 
Representative examples of FACS analysis at each time point. The two 
circles represent the two gated MO populations. (B) Total number of 
MOs/MPs was calculated from results obtained in A, and the number of 
isolated CD45+ cells were plotted to muscle weight. Results represent the 
means ± SD of three experiments. (C) Representative hematoxylin and 
eosin staining of muscle sections at various times after notexin injection. 
Bar, 50 μm.JEM VOL. 204, May 14, 2007  1059
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once necrosis has been removed and are associated with re-
generative myofi  bers (17, 28). Although the nature of ED1 
and ED2 MPs is not characterized, these results suggest that 
diff  erent MP subpopulations are associated with diff  erent stages 
of muscle repair.
In this study, we used in vivo tracing methods to analyze 
which MO subset was recruited after muscle injury, ex vivo 
phenotyping analyses to characterize the MO/MP profi  le 
during muscle regeneration, in vitro co-culture experiments 
to identify which MP phenotype was associated with myo-
genesis, and sequential in vivo MO/MP depletion studies 
to evaluate the respective roles of both circulating and i.m. 
MOs/MPs in skeletal muscle repair.
RESULTS
Two MO/MP subsets are sequentially present during 
muscle regeneration
MOs/MPs collected from skeletal muscle of the CX3CR1GFP/+ 
mouse (9, 15) were analyzed according to their GFP and Ly-6C 
expression during muscle regeneration. Normal muscle con-
tained little CX3CR1hi/Ly-6C− MOs/MPs ( 200 cells/mg 
of muscle). Notexin was injected in tibialis anterior (TA) 
muscles to induce the necrosis/regeneration process. As soon 
as 90 min after injury, CX3CR1lo/Ly-6C+ MOs/MPs were 
detected in muscle and rapidly invaded the tissue to reach a 
maximum point at 24 h after injury (25% of CD45+ cells). 
The CX3CR1lo/Ly-6C+ MO/MP population quickly de-
clined with time, whereas the CX3CR1hi/Ly-6C− MOs/MPs 
appeared and continuously increased to reach a plateau at 
day 7 accounting for 35% of CD45+ cells extracted from muscle 
at this time point (Fig. 1 A).
The MO/MP percentage among CD45+ cells is a relative 
quantifi  cation that does not refl  ect the amount of MOs/MPs 
actually present in muscle. Thus, we calculated from these data 
the total number of extracted GFP+ cells per milligram of 
muscle. Results indicated that the extent of the two MO/MP 
waves was diff  erent (Fig. 1 B), and this was confi  rmed by 
histological examination (Fig. 1 C). During the fi  rst 2 d, as 
injured myofi  bers became necrotic, 2,000 to 3,500 GFP+ 
cells/mg of muscle were counted. At 4 and 7 d, when myo-
genic cells proliferated and further diff  erentiated (Fig. 1 C), 
fi  ve- to sixfold more GFP+ MOs/MPs were found in muscle 
(12,000–16,000 cells/mg; Fig. 1 B). 10 d after injury, when 
centrally nucleated fi  bers were visible throughout the injured 
area (Fig. 1 C), the amount of GFP+ cells had dramatically 
declined to reach <2,000 GFP+ cells/mg of tissue (Fig. 1 B).
CX3CR1lo/Ly-6C+ and CX3CR1hi/Ly-6C− MO/MP populations 
display distinct proliferative and infl  ammatory profi  les
Between days 1 and 4 after injury, the number of Ly-6C− 
MOs/MPs increased 20-fold, while the number of Ly-6C+ 
MOs/MPs increased twofold (Fig. 1 B). We analyzed prolif-
eration of both subsets that were isolated from regenerating 
muscle by cell sorting (Fig. 2 A). Ki67 labeling showed that 
Ly-6C+ MOs/MPs never proliferated, whereas Ly-6C− 
MOs/MPs partially entered into cell cycle from day 2, and 
the number of proliferating cells doubled at day 4 and further 
decreased by twofold at day 7 (Fig. 2 B).
To examine the infl  ammatory profi  le of the two MO/MP 
populations, we analyzed cytokine expression of isolated 
Ly-6C− and Ly-6C+ MOs/MPs at day 4 after injury by 
RT-PCR. Results showed that Ly-6C+ MOs/MPs expressed 
IL-1β and, to a lesser extent, TNF-α transcripts more strongly 
than Ly-6C− MOs/MPs (Fig. 2 C). Conversely, Ly-6C− 
MOs/MPs expressed TGF-β1 and IL-10 more strongly than 
Ly-6C+ MOs/MPs (Fig. 2 C), indicating that Ly-6C+ MOs/
MPs had an infl  ammatory profi  le and Ly-6C− MOs/MPs had 
an antiinfl  ammatory profi  le.
Injured muscle only recruits CX3CR1lo/Ly-6C+ MOs/MPs 
that subsequently switch into antiinfl  ammatory CX3CR1hi/
Ly-6C− MOs/MPs and differentiate into MPs
We labeled each circulating subset with fl  uorescent latex beads 
(LXs) before injury, as previously described (12, 15).  Labeling 
of MOs does not alter their migratory capacities (12). After i.v. 
Figure 2.  Phenotype of Ly-6C+ and Ly-6C− MOs/MPs during muscle 
regeneration. Ly-6C+ and Ly-6C− MO/MP subsets were isolated by cell 
sorting at various times after injury. (A) Representative example of cell 
sorting of Ly-6C− (middle) and Ly-6C+ (right) cells from whole MOs/MPs 
(left) at day 4 after injury. (B) Ki67 immunostaining is expressed as the 
percentage of isolated MOs/MPs. (C) Expression of TNF-α, IL-1β, TGF-β1, 
and IL-10 was analyzed by RT-PCR in isolated populations at day 4 after 
injury. Corresponding band intensities are given as the means of 
three experiments. 1060  MONOCYTES/MACROPHAGES AND SKELETAL MUSCLE REPAIR | Arnold et al.
LX injection, circulating LX+ cells were CX3CR1hi/Ly-6C− 
MOs (Fig. 3 A, top, blood); LX+ cells were never detected in 
muscle after injury (Fig. 3 A, top, muscle), indicating that 
Ly-6C− MOs/MPs appearing in muscle at day 2 were not 
recruited from blood. After clodronate-encapsulated liposome 
(clo-lip) injection followed by LX injection, circulating LX+ 
cells were CX3CR1lo/Ly-6C+ MOs, as previously described 
(15). 36 h after notexin injection, LX+ cells were still Ly-6C+ 
MOs (95%) in the blood (Fig. 3 A, bottom, blood), while LX+ 
cells present within muscle were both Ly-6C+ and Ly-6C− 
(38 ± 2 and 61 ± 3%, respectively, based on three experiments; 
Fig. 3 A, bottom right, muscle). These data indicate that muscle 
Ly-6C− cells derived from early recruited Ly-6C+ MOs/MPs.
Several markers have been associated with MP phenotype 
transition at the time of resolution of infl  ammation. Among 
them, secretory leukocyte protease inhibitor (SLPI) is induced 
in MPs by proinfl  ammatory signals to trigger down-regulation 
of proinfl  ammatory cues (29–32). RT-PCR analysis showed 
that Ly-6C+ MOs/MPs strongly expressed SLPI compared 
with Ly-6C− MOs/MPs (62% increase of band intensity based 
on three experiments; Fig. 3 B) 4 d after injury. Inversely, per-
oxisome proliferator-activated receptor (PPAR) γ is expressed 
by MPs that down-regulate infl  ammation (33–35). Our results 
showed that PPAR-γ mRNA was strongly expressed by 
Ly-6C− compared with Ly-6C+ MOs/MPs (49% increase of 
band intensity based on three experiments; Fig. 3 B).
Forward and side scatter of the two MO/MP subsets iso-
lated at day 7 after injury showed that Ly-6C− MOs/MPs had 
higher side scatter and were larger than Ly-6C+ MOs/MPs 
(Fig. 3 C), in accordance with a maturation of the Ly-6C− 
subset. Analysis of diff  erentiation markers showed that Ly-
6C− MOs/MPs expressed CD11c and higher levels of F4/80 
(Fig. 3 C). Nearly all (> 90%) F4/80+ cells were CD11c+ and 
I-Ab+, and no positivity was observed for the dendritic cell 
marker DEC-205 (unpublished data). These results show that, 
contrary to Ly-6C+ MOs/MPs, Ly-6C− MOs/MPs exhib-
ited high levels of MP diff  erentiation markers.
Collectively, these results suggest that after muscle injury, 
infl  ammatory Ly-6C+ MOs are recruited from blood, con-
vert to antiinfl  ammatory Ly-6C− MOs/MPs that proliferate 
in situ, and further diff  erentiate into mature MPs.
Phagocytosis of muscle cell debris participates in MP 
phenotype transition
To study interactions between MPs and myogenic cells possi-
bly involved in MP phenotype transition, we used in vitro 
human cell co-cultures. Indeed, in vitro pro- and antiinfl  am-
matory MP activation states described in humans most likely 
correspond to Ly-6C+ and Ly-6C− MO/MP profi  les found 
in regenerating mouse muscle. Consistently, LPS/IFN-γ 
treatment of human MPs induced TNF-α (P < 0.05) and 
IL-1β (P < 0.05) secretion (Fig. 4 A), whereas dexametha-
sone (DEX)/IL-10 treatment induced IL-10 (P < 0.05) se-
cretion (Fig. 4 A), as previously shown (36, 37). Because 
diff  erentiating muscle cells secrete IL-4 (38), a key inducer 
of alternative activation of MPs (5), we tested IL-4 treatment, 
Figure 3.  Fate of Ly-6C+ and Ly-6C− MOs/MPs during muscle 
regeneration. (A) Circulating Ly-6C− (top) and Ly-6C+ (bottom) MOs 
were labeled with LX red microspheres and analyzed by fl  ow cytometry. 
LX+ CD45+ GFP+ cells (gates in all cells; left) were analyzed for Ly-6C 
expression (LX+ cells; right) in both blood and muscle at day 3 (for Ly-6C− 
labeling) and day 2 (for Ly-6C+ labeling) after injury. Results are represen-
tative of three experiments. (B) SLPI and PPAR-γ expression was analyzed 
by RT-PCR in Ly-6C+ and Ly-6C− MOs/MPs sorted at day 4 after injury. 
(C) Flow cytometry analysis of forward scatter (FSC)/side scatter (SSC) 
characteristics, F4/80 and CD11c expression of Ly-6C+ (blue), and Ly-6C− 
(red) MOs/MPs sorted at day 7 after injury (black dotted line, isotypic 
control). Results are representative of three experiments.JEM VOL. 204, May 14, 2007  1061
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which induced TGF-β1 secretion (Fig. 4 A), as previously 
shown (39).
 As a major role of MPs is to operate phagocytosis of dead 
cells, we evaluated the eff  ect of phagocytosis of muscle cell 
debris on the MP infl  ammatory profi  le. Upon phagocytosis 
of necrotic mpcs, LPS/IFN-γ–treated MPs both decreased 
their TNF-α secretion (P < 0.05) and increased their TGF-
β1 secretion (P < 0.03; Fig. 4 B). We attempted to inhibit 
phagocytosis of proinfl  ammatory MPs by colchicine (40), cy-
tochalasin D (41), and recombinant Annexin V (42). Colchi-
cine failed to inhibit phagocytosis, and MPs changed their 
cytokine secretion upon mpc debris phagocytosis, as in un-
treated cells (Fig. 4 C). Conversely, phagocytosis was inhibited 
in the presence of cytochalasin D or recombinant Annexin V; 
in these conditions, TNF-α and TGF-β1 secretion did not 
change in the presence of mpc debris (Fig. 4 C). These data 
indicate that phagocytosis of mpc debris induced a switch of 
the MP phenotype toward an antiinfl  ammatory profi  le, as 
previously shown for other cell types (43–46).
We also evaluated whether interactions with living mpcs 
may infl  uence MP phenotype. Neither addition of mpcs to pre-
viously activated MPs nor addition of mpcs before MP activa-
tion substantially altered the MP phenotype (unpublished data). 
These data show that mpcs neither modifi  ed the MP activation 
state nor prevented acquisition of any given MP phenotype.
Infl  ammatory MPs increase mpc growth, whereas 
antiinfl  ammatory MPs stimulate their differentiation
In co-culture experiments, we analyzed mpc behavior de-
pending on MP activation state. We have previously shown 
that untreated MPs stimulate mpc growth and proliferation 
(26). As shown in Fig. 5, mpc diff  erentiation (Fig. 5 C) and 
fusion (Fig. 5 D) were also increased by untreated MPs (P ≤ 
0.05). LPS/IFN-γ–treated MPs were more potent in enhanc-
ing mpc growth (63%; P < 0.05; Fig. 5 A), and accordingly, 
they enhanced mpc proliferation, as shown by increased BrdU 
incorporation (25%; P < 0.05; Fig. 5 B). Inversely, both myo-
genin expression (Fig. 5 C) and myotube formation (Fig. 5 D) 
were strongly reduced (58 and 68%, respectively; P < 0.05), 
indicating an inhibition of diff  erentiation by infl  ammatory 
MPs. IL-4–treated MPs slightly reduced mpc proliferation 
(14%; P < 0.05; Fig. 5 B), whereas they stimulated myogenin 
expression (28%; P < 0.05; Fig. 5 C) and stimulated myo-
tube formation (158%; P < 0.05; Fig. 5 D) compared with 
untreated MPs. DEX/IL-10–treated MPs did not stimulate 
growth (Fig. 5 A) and proliferation (Fig. 5 B) compared with 
untreated MPs but presented a strong prodiff  erentiating activ-
ity, as assessed by increased myogenin expression (52%; P < 
0.05; Fig. 5 C) and increased myotube formation (136%; P < 
0.01; Fig. 5 D). These results strongly suggest that the activa-
tion state of MPs may monitor the myogenic process.
MO/MP presence is mandatory for skeletal 
muscle regeneration
We took advantage of the CD11b–diphtheria toxin recep-
tor (DTR) mouse to study the respective roles of MO/MP 
subsets during muscle regeneration in vivo, because i.m. 
injection of clo-lip is toxic for myogenic cells (unpublished 
data). In CD11b-DTR mice, MOs (and possibly tissue 
MPs, depending on the way of injection) are depleted after 
DT injection (47). After a single i.v. DT injection, circu-
lating MO loss occurred from 6 h and reached a maximum 
Figure 4.  Phagocytosis and cytokine secretion by activated MPs. 
Cytokine secretion was evaluated by ELISA in MP-conditioned medium. 
(A) Cytokine secretion by untreated (NT) and LPS/IFN-γ–, IL-4–, and DEX/
IL-10–treated MPs. (B) Cytokine secretion by untreated (NT) and LPS/IFN-γ–
treated MPs after phagocytosis of muscle cell debris. (C, left) Phagocytosis 
of LXs by LPS/IFN-γ–treated MPs incubated or not (none) with colchicine 
(colc), cytochalasin D (cyt D), or recombinant Annexin V (Ann.V). (right) 
Cytokine secretion by LPS/IFN-γ–treated MPs after phagocytosis of mus-
cle cell debris in the presence of the same effectors. Results represent the 
means ± SEM of three experiments.1062  MONOCYTES/MACROPHAGES AND SKELETAL MUSCLE REPAIR | Arnold et al.
at 12 h, which lasted 12 h longer, with subsequent restoration 
and normalization at 48 h (Fig. 6 A). At maximum depletion, 
75–80% of cells in the MO gate had disappeared (Fig. 6 A), 
as did F4/80+, CD11b+, and Ly6C+ cells (not depicted). 
The time course of postinjury muscle regeneration in un-
treated CD11b-DTR mice was similar to that of the C57BL/6 
mouse shown in Fig. 1 until day 4, but centrally nucleated 
myofi  bers appeared earlier in CD11b-DTR than in C57BL/6 
mice (day 7 vs. 10; Fig. 6 B). When DT was simultaneously 
injected at (Fig. 6 C) or 12 h before (Fig. 6 D) muscle injury, 
necrotic fi  bers were removed more slowly, and regeneration 
was impaired with the appearance of adipose cells (Fig. 6, C 
and D; and Fig. 7). After double DT injection, both 12 h be-
fore and simultaneously at notexin injection (which induced 
a MO depletion lasting 0–24 h after injury), almost no MO/
MP infi  ltration was observed (Fig. 6 E). None of the hallmarks 
of regeneration were detected, and persistence of necrotic 
fi  bers was observed until day 7 (Fig. 6 E and Fig. 7), although 
circulating MOs reappeared in the circulation from day 2 after 
injury (not depicted). When DT was injected 4 d after no-
texin, no diff  erence was observed compared with the con-
trol (Fig. 6 B and Fig. 7), indicating that circulating MOs 
were no longer recruited into muscle at this time. Notably, 
i.v.-injected DT did not notably aff  ect i.m. MOs/MPs, as 
shown by unchanged expression of both F4/80 and CD11b 
by CD45+ cells isolated from muscle (Fig. 6 F, inset).
We attempted to target i.m. antiinfl  ammatory MOs/MPs 
at a time when phagocytosis of necrotic myofi  bers is fi  nished 
(Fig. 6 B and Fig. 7 A). To assess MP depletion in muscle, 
fl  ow cytometric analysis of CD45+ cells was performed 24 h 
after a single i.m. DT injection. The total number of F4/80+ 
cells present in muscle was diminished by 25% after DT 
  injection (especially F4/80hi cells, which were diminished by 
75%; P < 0.05; Fig. 8 A), indicating that these diff  erentiated 
FSChiF4/80hi MPs, corresponding to Ly-6C− MPs, were tar-
geted by DT. However, the total number of CD45+ cells in-
creased by twofold in DT- versus PBS-injected muscle (Fig. 
8 A), indicating that i.m. DT injection induced a secondary 
infl  ammation accompanied by the recruitment of F4/80− leu-
kocytes (likely neutrophiles and F4/80lo/− MOs). Consistently, 
histological examination of whole TA muscle 4–5 d later 
showed an area in which new cycles of regeneration were visi-
ble, as assessed by the presence of necrotic and basophilic fi  bers 
(Fig. 8 B,  arrow). This area was restricted to the site of needle 
puncture and was therefore excluded from the analysis to avoid 
counting of small regenerating myofi  bers coming from the sec-
ondary lesion (Fig. 8 B). The diameter of centrally nucleated 
regenerating myofi  bers was evaluated in the rest of the TA and 
was found to be reduced by 41% in DT- versus PBS-injected 
muscle (30.8 vs. 18.2 μm, respectively; P < 0.001; Fig. 8 C).
D  I  S  C  U  S  S  I  O  N 
In the present study, we have shown that (a) injured skeletal 
muscle selectively recruits Ly-6C+ circulating MOs that 
exhibit an infl  ammatory profi  le; (b) within muscle, Ly-6C+ 
MOs switch their phenotype to acquire an antiinfl  ammatory 
profi  le, with phagocytosis of muscle cell debris being most 
likely involved in this transition; (c) as necrosis disappears 
from the injured area, antiinfl  ammatory Ly-6C− MOs/MPs 
proliferate and further diff  erentiate into MPs; (d) in vitro, in-
fl  ammatory MPs enhance myogenic cell proliferation and 
repress their diff  erentiation, whereas antiinfl  ammatory MPs 
Figure 5.  Effects of activated MPs on mpc fate. mpcs were 
co-cultured with untreated (NT) and LPS/IFN-γ–, IL-4–, and DEX/IL-10–
treated MPs and further analyzed for their (A) growth, (B) proliferation, 
(C) differentiation, and (D) fusion. All parameters were analyzed at day 3 of 
co-culture except for BrdU incorporation, which was monitored during 24 h 
of co-culture. Results represent the means ± SEM of three experiments. 
Asterisks above bars indicate signifi  cant differences (P < 0.05).JEM VOL. 204, May 14, 2007  1063
ARTICLE
Figure 6.  Effects of circulating MO depletion on skeletal muscle 
regeneration. (A, left) Kinetics of circulating MO depletion after one i.v. DT 
injection. Results represent the means ± SD of at least four experiments. 
(right) Examples of FACS analysis of blood before (−DT) and 18 h after 
i.v. DT injection (+DT). Circles show MO gate. (B–F) Notexin (Nx) was 
injected into the TA of CD11b-DTR mice at day 0, and DT was injected 
i.v. at various times, as indicated by the red arrows. Muscle histology 
was analyzed until day 7 after hematoxylin and eosin staining. 
Results are representative of at least two independent experiments. 
(F, inset) CD45+ cells were isolated from muscle and analyzed for 
F4/80 and CD11b expression 24 h after an i.v. DT (blue line) or PBS (red 
line) injection at day 4 after injury (black dotted line, isotypic control). 
Bar, 50 μm.1064  MONOCYTES/MACROPHAGES AND SKELETAL MUSCLE REPAIR | Arnold et al.
stimulate myogenesis and fusion; and (e) in vivo depletion of 
circulating MOs at the time of injury totally prevents muscle 
regeneration, whereas later depletion of i.m. MPs decreases 
the diameter of regenerating fi  bers.
It has been shown that the CX3CR1lo/Ly-6C+ MO 
population is recruited in injured or infl  amed tissues (9, 
13, 48). Our experiments using LX-labeled circulating MOs 
showed that CX3CR1lo/Ly-6C+ MOs were selectively re-
cruited rapidly after muscle injury. Mouse CX3CR1lo/Ly-
6C+ MOs and their human analogues bear several chemokine 
receptors, including CC chemokine receptor (CCR) 2, CCR1, 
CCR4, CCR7, CXC chemokine receptor 1, and CXC che-
mokine receptor 2 (9). The corresponding chemokines are 
expressed by muscle tissue during the fi  rst days after injury 
(the cytokine expression profi  le is available at http://pepr
.cnmcresearch.org) (22, 49, 50). Monocyte chemoattractant 
protein–1 has been particularly involved in MO recruitment 
by injured muscle (19, 20). We did not evidence recruitment 
of CX3CR1hi/Ly-6C− MOs from blood to muscle. More-
over, transient depletion of circulating MOs during the fi  rst 
0–24 h after muscle injury showed no subsequent MP infi  l-
tration despite reconstitution of the pool of circulating MOs. 
This suggests that CX3CR1lo/Ly-6C+ MO/MP recruitment 
takes place early after injury (i.e., within 2–3 d after injury).
Our experiments showed that initially LX-labeled 
CX3CR1lo/Ly-6C+ MOs converted to CX3CR1hi/Ly-6C− 
MOs/MPs from day 2 after injury, indicating a phenotype 
transition of MOs/MPs within muscle. Consistently, MP dif-
ferentiation markers were weakly expressed by CX3CR1lo/Ly-
6C+ MOs/MPs and markedly expressed by CX3CR1hi/
Ly-6C− MOs/MPs (see below). We propose that CX3CR1lo/
Ly-6C+ cells, which exhibit an infl  ammatory phenotype 
(expressing TNF-α and IL-1β), progressively lose Ly-6C ex-
pression while converting to antiinfl  ammatory MOs/MPs (ex-
pressing TGF-β1 and IL- 10). These data are in accordance with 
the cytokine mRNA analysis of postinjured muscle extract 
(available at http://pepr.cnmcresearch.org) (51): TNF-α and 
IL-1β expression peaks at days 2–3 after injury, whereas IL-10 
and TGF-β1 expression increases from day 2 after injury and is 
maintained throughout regeneration. MP phenotype conversion 
observed in skeletal muscle further supports previous in vitro 
evidence that MPs are capable of rapid adaptation to changing 
environments (4, 6–8) and in vivo demonstration that MPs alter 
their phenotype according to their tissue environment (52).
MPs participate in both amplifi  cation of infl  ammation at 
the time of injury and down-regulation of the infl  ammatory 
response to avoid excess tissue damage (31, 53, 54). MP stop 
signals associated with the resolution of infl  ammation in-
clude induction of negative regulators of infl  ammation  in 
MPs by environmental cues and nonphlogistic phagocytosis. 
As shown herein, both likely operate during skeletal muscle 
regeneration. SLPI is considered as a brake on the response 
of MPs to infl  ammation (29, 31). Its expression is induced 
by LPS and IL-6 and leads to inhibition of NO and TNF-α 
production (30). In vivo, the highest SLPI synthesis occurs 
during the proinfl  ammatory phase and, thus, anticipates an 
increase in TGF-β1 and IL-10 production (32). Accordingly, 
we have shown that CX3CR1lo/Ly-6C+ MOs/MPs ex-
pressed more SLPI than CX3CR1hi/Ly-6C− cells. Another 
marker associated with the resolution of infl  ammation by 
Figure 7.  Quantitative analysis of muscle regeneration after 
circulating MO depletion. CD11b-DTR mice were treated as in Fig. 6, 
and in each case the number of (A) necrotic myofi  bers, (B) phagocyted 
myofi  bers, (C) regenerating basic myofi  bers, and (D) centrally nucleated 
regenerating myofi  bers was evaluated. Closed squares represent the con-
trol corresponding to Fig. 6 B; open diamonds represent simultaneous DT 
and notexin injections corresponding to Fig. 6 C; open triangles represent 
a DT injection 12 h before notexin injection corresponding to Fig. 6 D; 
open squares represent a double DT injection corresponding to Fig. 6 E; 
and closed circles represent a DT injection 4 d after notexin injection cor-
responding to Fig. 6 F. Results are expressed as the percentage of total 
counted myofi  bers and are the means of at least two experiments.JEM VOL. 204, May 14, 2007  1065
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MPs is PPAR-γ. Fatty acids and prostaglandin metabolites 
bind to PPAR-γ in activated MPs, which triggers inhibition 
of both inducible NO synthase and release of proinfl  ammatory 
cytokines (33, 35), thus conferring antiinfl  ammatory pro  p-
erties to PPAR-γ (34). In this paper, we showed that anti-
infl  ammatory  CX3CR1hi/Ly-6C− MOs/MPs strongly 
expressed PPAR-γ. Nonphlogistic phagocytosis by MPs is 
another signal for switching to healing (31). Binding and 
phagocytosis of apoptotic cells inhibit secretion of proin-
fl   ammatory mediators and stimulate secretion of TGF-β1 
and IL-10 by infl  ammatory MPs (43–46). Induction of an 
antiinfl   ammatory process by phagocytosis of necrotic cells 
depends on the cell type ingested (42, 43, 55). We showed 
that both unstimulated and infl  ammatory MPs adopted an 
antiinfl  ammatory profi  le upon phagocytosis of necrotic muscle 
cell debris and that inhibition of MP phagocytosis prevented 
this phenotype switch. Collectively, these results strongly 
suggest that recruited infl  ammatory CX3CR1lo/Ly-6C+ MOs/
MPs convert to antiinfl  ammatory CX3CR1hi/Ly-6C− MOs/
MPs upon both ingestion of muscle cell debris and expression 
of stop signals extinguishing infl  ammation.
Our results showed that once switched, CX3CR1hi/Ly- 
6C− MOs/MPs actively proliferated, therefore contributing 
to the large amounts of MOs/MPs observed in muscle at days 
4–7 after injury. In vitro, MP proliferation is inhibited by 
infl  ammatory mediators (LPS, IFN-γ, NO, and IL-6) and is 
stimulated by TGF-β1 (56–58). Thus, proliferation of re-
cruited MOs/MPs may be caused by changes in their envi-
ronment, although as yet unknown mechanisms related to the 
change of phenotype cannot be excluded. Later during muscle 
regeneration (day 7), CX3CR1hi/Ly-6C− MO/MP proliferation 
slowed down simultaneously with the complete diff  erentiation 
Figure 8.  Effects of i.m. DT injection on skeletal muscle regeneration. 
Notexin (Nx) was injected into the TA of CD11b-DTR mice at day 0, and DT 
was injected in the same muscle at day 5 (A) and days 5 and 6 (B and C). 
(A) 24 h after a single i.m. DT injection, CD45+ cells were isolated from 
muscle and analyzed for F4/80 expression. Red circles enclose FSChi/F4/80hi 
cells. (B) Reconstituted whole view of TA muscle at day 10 after Notexin 
injection (hematoxylin and eosin staining), presenting hallmarks of 
secondary regeneration restricted to the site of needle puncture (arrow). 
(right) Hatched area represents the area excluded from analysis. Bar, 
200 μm. (C) PBS- and DT-injected muscles were analyzed at day 10 after 
injury for myofi  ber diameter evaluation (hematoxylin and eosin staining). 
Quantifi  ed results are given for three independent experiments, with each 
point corresponding to a fi  eld (red bars represent the means). Bar, 50 μm.1066  MONOCYTES/MACROPHAGES AND SKELETAL MUSCLE REPAIR | Arnold et al.
into MPs, as shown by their strong F4/80 expression (59). Al-
most all F4/80+ cells were also positive for CD11c and MHCII, 
as previously observed after infl  ammation in various organs (60, 
61), and were DEC-205−. In the blood, Ly-6C− MOs, which 
come from Ly-6C+ cells, are also CD11c+ (12). Therefore, the 
appearance of CD11c+ cells in the muscle may be a recapitula-
tion of conversion from Ly-6C+/CD11c− to Ly-6C−/CD11c+ 
MOs within the tissue. Thus, proliferating CX3CR1hi/Ly-6C− 
MOs/MPs and diff  erentiating CX3CR1hi/Ly-6C− MPs are 
associated with the regenerative phase of muscle repair.
Depending on the context, MPs may have supportive or 
deleterious eff  ects on cells: in chronic diseases, including those 
aff  ecting skeletal muscle, MPs are deleterious (62, 63), whereas 
they support tissue repair in muscle and other various tissues, 
including the liver, brain, peripheral nerve, and epithelium 
(19–22, 64–67). With the exception of regulation of infl  am-
mation, studies documenting a direct role of MPs on cell be-
havior are scant and include intestinal progenitor proliferation 
(65), erythroblast proliferation and maturation (68), and oli-
godendrocytic diff  erentiation and myelination (69). In vitro 
studies have shown that the MP activation state may direct 
neural progenitor diff  erentiation toward either neurogenesis 
or oligodendrogenesis (70). Our results substantiate the view 
that MP function may be related to an activation state. In co-
culture experiments, infl  ammatory MPs (the counterpart of 
infl  ammatory CX3CR1lo/Ly-6C+ cells observed in vivo) 
stimulated mpc proliferation and inhibited their diff  erentiation. 
Inversely, IL-4 treated and antiinfl  ammatory MPs exhibited a 
strong diff  erentiating activity on mpcs, assessed by both stim-
ulation of myogenic program and increase of fusion into 
multinucleated cells. Molecular mechanisms involved in these 
processes are currently under investigation. It is likely that 
cytokines released by activated MPs infl  uence myogenic cell 
behavior: TNF-α is mitogenic for myoblasts and inhibits their 
diff  erentiation (71, 72), IL-1β impairs myogenic diff  erentia-
tion through insulin-like growth factor–1 (73), and in vitro 
eff  ects of TGF-β1 are more controversial, although in vivo 
neutralization of TGF-β1 in regenerating muscle was shown 
to reduce the diameter of regenerating myofi  bers (74). Beyond 
cytokines, cyclooxygenase 2 and its metabolites may also play 
a role, as they were shown to be fusogenic and necessary for 
good muscle repair (75–77).
Previous in vivo studies using diff   erent injury models 
have shown that partial reduction of MO/MP entry into 
injured muscle hinders muscle regeneration, as shown by a 
delay in the appearance of regenerating myofi  bers and the 
persistence of intermuscular adipocytes (19–22). We observed 
similar features upon partial inhibition of MO recruitment in 
toxic-induced muscle regeneration. Moreover, when nearly 
no MO/MP was allowed to enter damaged muscle, myofi  -
bers remained in the necrotic state, indicating the indispens-
able role of MPs in muscle repair. Interestingly, despite the 
normalized level of circulating MOs from day 2 after injury, 
no delayed recruitment was observed, suggesting that signals 
governing MO recruitment are only transiently expressed by 
the damaged tissue, as was recently documented in ultraviolet-
injured skin (48). Accordingly, depletion of circulating MOs 
at day 4 after injury had no eff  ect on muscle regeneration. On 
the other hand, depletion of i.m. antiinfl  ammatory F4/80hi 
MOs/MPs at the time of regeneration (i.e., once phago  cytosis 
of necrotic myofi  bers is achieved) reduced the diameter of the 
centrally nucleated regenerating myofi   bers, indicating that 
these MOs/MPs were involved in fi  ber growth, in accordance 
with our in vitro data.
In conclusion, our data demonstrate a phenotype transi-
tion operated by recruited MOs/MPs during resolution of 
infl  ammation and tissue repair, which is associated with 
changes in their functions. We propose sequential involve-
ments of these two phenotypically distinct MP populations 
during skeletal muscle repair as follows: within the fi  rst 24–48 h 
after injury, skeletal muscle recruits infl  ammatory circulat-
ing MOs, which stimulate myogenic cell proliferation and 
prevent their diff  erentiation. While they are exposed to an 
infl  ammatory environment and operate phagocytosis of mus-
cle cell debris, infl  ammatory MOs/MPs convert to antiin-
fl  ammatory MOs/MPs. As phagocytosis of necrotic myofi  bers 
is fi  nished, these antiinfl  ammatory MOs/MPs actively prolif-
erate and further diff  erentiate into antiinfl  ammatory MPs that 
sustain myogenic diff  erentiation and myofi  ber growth in ad-
dition to their protective eff  ect on diff  erentiating myotubes 
(27) and their eff  ect on fi  ber membrane repair (78).
MATERIALS AND METHODS
Animals. C57BL/6, CX3CR1gfp/+ (9), and CD11b-DTR (provided by J.S. 
Duffi   eld, Harvard Medical School, Boston, MA) (47) mice were bred and used 
according to French legislation. Experiments were conducted at 4–8 wk of age.
Muscle injury and muscle preparation. 10 μl notexin (25 μg/ml in 
PBS; Latoxan) was injected in the TA. For histological analysis, muscles 
were prepared as previously described (27). Quantitative analysis of muscle 
regeneration was performed on the entire injured area: approximately seven 
fi  elds (20× objective; PL Flustar; Carl Zeiss MicroImaging, Inc.) were ana-
lyzed in each mouse, representing 300–400 fi  bers per mouse. Myofi  ber di-
ameter was evaluated after collagen IV immunolabeling (see Immunolabeling) 
on approximately seven fi  elds (20× objective) in each mouse. The small diame-
ter of only centrally nucleated myofi  bers was evaluated in late-regenerating 
muscle (nonhatched area in Fig. 8 B) with Axiovision 4.6 software (Carl 
Zeiss MicroImaging, Inc.), representing 250–350 fi  bers per mouse. In PBS-
injected mice, the punctured fascicule was omitted from analysis.
Isolation of MOs/MPs from muscle. Fascia of the TA was removed. 
  Muscles were dissociated in DMEM containing collagenase B 0.2% (Roche 
Diagnostics GmbH) and trypsine-EDTA 0.2% at 37°C for 45 min twice, fi  l-
tered, and counted. CD45+ cells were isolated using magnetic sorting (Miltenyi 
Biotec) and stained with PE- or PC5-conjugated anti-Gr1 antibody (which reacts 
with Ly-6C and Ly-6G, but only Ly-6C is expressed by MOs; eBioscience). 
Cells were sorted using a cell sorter (Epics Elite; Beckman Coulter). Popula-
tions presenting >90% purity were used. In some experiments, PE-conjugated 
CD11c, I-Ab (BD Biosciences) and F4/80 (AbD Serotec) antibodies were used. 
Analysis was performed with a cytometer (FACSCalibur; BD Biosciences).
Labeling of blood MOs. Labeling of circulating MOs was performed ex-
actly as previously described (15) with plain microspheres (Fluoresbrite 
Polychromatic Red Microspheres 0.5μm, 2.5% solids; PolySciences, Inc.) 
and clo-lip, which were prepared as previously described (79). Clodronate 
was a gift of Roche Diagnostics GmbH.JEM VOL. 204, May 14, 2007  1067
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Depletion of circulating MOs and i.m. MPs. 12 ng/g DT was i.v. in-
jected into CD11b-DTR mice. Blood was retroorbitally harvested at vari-
ous times after injection, and cells were labeled with anti-CD11b, anti-Gr1, 
and F4/80 antibody and analyzed by fl  ow cytometry. Because of high inter-
individual variations (3–12% of PBMCs), the number of circulating MOs in 
control mice was normalized to 5% of PBMCs for each series (mean calcu-
lated with >25 mice). To deplete infi  ltrated MOs/MPs, 25 ng/g DT in 
<10 μl was i.m. injected at days 5 and 6 after injury. Controls included 
  injection of PBS.
Immunolabeling. Muscle slides were incubated with anticollagen IV anti-
body (1:50; Chemicon International, Inc.) revealed with Cy5-conjugated 
anti–rabbit antibody. Mouse-sorted cells were centrifugated on slides and 
  labeled with 1 μg/ml anti-Ki67 antibody (Abcam plc), revealed with FITC-
conjugated anti–rabbit antibody. Cultured human mpcs were incubated with 
60 μg/ml antidesmin antibody (Abcam plc), revealed by a Cy3-conjugated anti–
rabbit antibody, and with 10 μg/ml antimyogenin antibody (BD Biosciences), 
revealed by a biotinylated anti–mouse (Vector Laboratories) and by dichlo-
rotriazinglaminofl  uorescein-streptavidin (Beckman Coulter). Controls included 
incubation with whole rabbit or mouse IgGs. Other secondary antibodies and 
IgGs were obtained from Jackson ImmunoResearch Laboratories.
RT-PCR. Total RNA was prepared from sorted cells using the RNeasy mini 
kit (QIAGEN). 0.5 μg of total RNA was reverse transcripted using Super-
script II reverse transcriptase and amplifi  ed with a platinum Taq DNA poly-
merase (Invitrogen) and the following specifi  c primers (sense and antisense, 
respectively): β2 microglobulin, 5′-C  A  G  T  T  C  C  A  C  C  C  G  CCTCAC-3′ and 
5′-C  A  C  A  T  G  T  C  T  C  G  A  T  C  C  C  A  G  -3′; TNF-α, 5′-T  T  C  C  A  G  A  T  T  C  T  T  C-
C  C  T  G  A  G  G  T -3′ and 5′-T  A  A  G  C  A  A  A  A  G  A  G  G  A  G  G  C  A  A  C  A  -3′; IL-1β, 
5′-T  G  A  C  G  T  T  C  C  C  A  T  T  A  G  A  C  A  A  C  T  G  -3′ and 5′-C  C  G  T  C  T  T  T  C  A  T  T  A-
C  A  C  A  G  G  A  C  A  -3′; TGF-β1, 5′-G  A  G  A  C  G  G  A  A T A  C  A  G  G  G  C  T  T  T  C  -3′ and 
5′-T  C  T  C  T  G  T  G  G  A  G  C  T  G  A  A  G  C  A  A  T -3′; IL-10, 5′-A  C  C  A  G  C  T  G  G  A  C  A-
A  C  A  T  A  C  T  G  C  -3′ and 5′-T  C  A  C  T  C  T  T  C  A  C  C  T  G  C  T  C  C  A  C  T -3′; SLPI, 
5′-C  C  T  T  A  A  G  C  T  T  G  A  G  A  A  G  C  C  A  C  A  -3′ and 5′-A  G  C  A  C  T  T  G  T  A  T  T  T  G-
C  C  G  T  C  A  C  ; and PPAR-γ, 5′-A  A  G  A  G  C  T  G  A  C  C  C  A  A  T  G  G  T  T  G  -3′ and 
5′-G  G  A  T  C  C  G  G  C  A  G  T  T  A  A  G  A  T  C  A  -3′. Amplifi   cation was performed at 
94°C, 60°C, and 72°C for 1 min for each step for 30 cycles. 10 μl of amplifi  -
cation products was subjected to electrophoresis on a 2% agarose gel contain-
ing ethidium bromide for visualization. Quantifi  cation was performed by 
using Image software (Scion).
Human mpc culture. Culture media components were purchased from 
Invitrogen. Human mpcs were cultured from muscle samples at the time of 
corrective surgery, in conformity with French legislation (Code de la Santé 
Publique, livre II), as previously described (26).
Human MP cell culture. MPs were diff  erentiated from MOs isolated from 
human blood, as previously described (26). Diff  erentiated MPs were further 
cultured in either RPMI 1640 medium containing 15% FBS or advanced 
RPMI 1640 medium containing 0.5% FBS (supplemented with 1% sodium 
pyruvate, 10 mM Hepes, 50 μM β-mercaptoethanol, 1% nonessential amino 
acids, 100× 1% vitamins). MPs were treated, or not, for 48 h with either 
1 μg/ml LPS (Sigma-Aldrich) and 10 ng/ml IFN-γ (PeproTech), or 10 ng/ml 
IL-4 (PeproTech) or 80 ng/ml DEX (Sigma-Aldrich) and 10 ng/ml IL-10 
(PeproTech).
Phagocytosis. mpc necrosis was induced by H2O treatment for 1 h at 
37°C. 100% of cells were propidium iodide positive. Necrotic mpcs were 
seeded on MPs (fi  ve dead mpcs for one MP) for 3 h at 37°C. MP cultures 
were washed three times to remove noningested material and further 
cultured in serum-free advanced RPMI 1640 supplemented medium over 
24 h to make conditioned media. In some experiments, cells were treated, as 
previously described, with 10 μg/ml colchicine (Sigma-Aldrich) (40), 1 μg/ml 
cytochalasin D (Sigma-Aldrich) (41), or 40 μg/ml recombinant Annexin V 
(BD Biosciences) (42). Phagocytosis was quantifi  ed in the same conditions 
after incubation with fl  uorescent microspheres (as described in Labeling of 
blood MOs). The number of LX+ cells was quantifi  ed under an inverted 
microscope and expressed as the percentage of total cells.
Co-cultures. mpcs were plated on previously prepared MP cultures (3:1 
MP/mpc ratio) in advanced RPMI 1640 supplemented medium, except in 
some experiments in which MPs and mpcs were seeded together before MP 
treatment was applied, as described in Human MP cell culture.
mpc behavior. mpc growth was evaluated as previously described (26). 
mpc proliferation was estimated by BrdU incorporation (Roche Diagnostics 
GmbH). mpc diff  erentiation was evaluated by counting the number of myo-
genin+ cells among desmin+ cells. mpc fusion was estimated by counting the 
number of nuclei per myotube.
Statistical analyses. All experiments were performed using at least three 
diff  erent cultures or animals in independent experiments. The Student’s 
t test was used for statistical analyses. P < 0.05 was considered signifi  cant.
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